Penn Medicine Provider
Radiation Oncology
James Metz, MD
5.0
(37)
Accepting new patients
Sees patients age 18 and up
Penn Radiation Oncology Perelman - 2nd Floor

About me

  • Chair, Radiation Oncology
  • Henry K. Pancoast Professor of Radiation Oncology

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: Cooper University Hospital
  • Residency: University of Pennsylvania School of Medicine

What my patients think about me

Average Rating
5.0

37 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

February 2025
5.0
5.0
i am very fortunate to have a doctor like dr. metz. he's extremely professional and aware all my issues before i meet him. my wife was with me today and she agreed that dr. metz is amazing.
June 2024
5.0
5.0
dr metz has common sense approach, is a very good communicator and is as knowledgeable as any doctor in his specific field.
April 2024
5.0
5.0
i'm very fortunate to have a doctor like dr. metz and i appreciate him greatly.
April 2024
5.0
5.0
made me feel very comfortable and explained every part of the procedure, and answered all my questions

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Metz is a Penn Medicine physician.

Qualifications and experience

My research

Verginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM FLASH proton reirradiation, with or without hypofractionation, reduces chronic toxicity in the normal murine intestine, skin and bone. , RadioTher. Oncology : 2025


Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, Zhang D, Zheng H, Zhang, R, Ma R, Ngo G, Zhang L, Diffenderfer ES, Motlagh SAO, Kim MM, Minn AJ, Dorsey JF, Foster JB, Metz J, Koumenis C, Kirsch DG, Gong Y, Fan Y. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. , Nat. Cancer : 2025


Lee G, Nelson B, Koenig J, Plastaras JP, Metz JM, Yeap BY, Zhang Y, Drapek, LC, Baglini C, Ryan DP, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, Ben-Josef, E, Hong TS, Kharofa JR, Wo JY. Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of 2 Prospective Trials. , Int. J Radiation Oncology-Biology-Physics: 2025


Kim K, Kim MM, Skoufos G, Diffenderfer ES, Motlagh SAO, Kokkorakis M, Koliaki, I, Morcos G, Shoniyozov K, Griffin J, Hatzigeorgiou AG, Metz JM, Lin A, Feigenberg SJ, Cengel KA, Ky B, Koumenis C, Verginadis II FLASH Proton Radiation Therapy Mitigates Inflammatory and Fibrotic Pathways and Preserves Cardiac Function in a Preclinical Mouse Model of Radiation-Induced Heart Disease. , Int. J Radiation Oncology-Biology-Physics: 2024


Anstadt EJ, Carmona R, Berlin E, Yegya-Raman N, Venigalla S, Reddy V, Williams GR, Leibensperger MR, Wojcieszynski A, Baumann BC, Lee MK, Plastaras, JP, Furth EE, Mell LK, Metz JM, Ben-Josef E. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. , Cancer : 2024


Amit U, Shagun M, Plastaras JP, Metz JM, Karasic TB, Lubas MJ, Ben-Josef E. Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy. , Radiation Oncology : 2024


erginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei, Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM. FLASH proton reirradiation, with or without hypofractionation, mitigates chronic toxicity in the normal murine intestine, skin, and bone. , bioRxiv [Preprint]: 2024


Hartsell WF, Simone CB 2nd, Godes D, Maggiore J, Mehta MP, Frank SJ, Metz JM, Choi JI. Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012 to 2021) From the National Association for Proton Therapy. , Int. J Radiation Oncology-Biology-Physics : 2024


Chowdhury P, Velalopoulou A, Verginadis II, Morcos G, Loo PE, Kim MM, Motlagh SAO, Shoniyozov K, Diffenderfer ES, Ocampo EA, Putt M, Assenmacher CA, Radaelli E, Lu J, Qin L, Liu H, Leli NM, Girdhani S, Denef N, Vander Stappen F, Cengel KA, Busch TM, Metz JM, Dong L, Lin A, Koumenis C. Proton FLASH Radiotherapy Ameliorates Radiation-induced Salivary Gland Dysfunction and Oral Mucositis and Increases Survival in a Mouse Model of Head and Neck Cancer. , Mol Cancer Therapy. : 2024


Bakhtiar M, Butala AA, Berlin EE, Metz JM, Bradley JD, Jones JA, Lukens JN, Paydar I, Taunk NK Factors Associated With and Characteristics of Patients Receiving Proton Therapy at the End of Life. , International Journal Particle Therapy : 2024